Stepan Company (SCL) Q1 2025 earnings summary

Executive summary

• Net income for Q1 2025 was $19.7M, up 42% year-over-year; adjusted net income was $19.3M, up 32%, driven by strong growth in surfactants and specialty products, with polymers seeing a slight decline and higher pre-operating expenses at the Pasadena site.

• EBITDA reached $58.0M, up 16% year-over-year; adjusted EBITDA was $57.5M, up 12%, supported by volume growth in surfactants, polymers, and MCT.

• Global sales volume increased 4% year-over-year, with surfactants up 3%, polymers up 7%, and MCT up 4%; agricultural and oilfield markets saw double-digit volume growth.

• Free cash flow was negative $25.8M, reflecting higher working capital and anticipation of tariffs.

• The new Pasadena, Texas alkoxylation site is operational, supporting specialty business growth, with full contribution expected in the second half of 2025.

Financial highlights

• Net sales for Q1 2025 were $593.3M, up 8% year-over-year, driven by a 4% volume increase and higher selling prices.

• Adjusted net income was $19.3M ($0.84 per diluted share), up from $14.7M ($0.64 per share) in Q1 2024.

• Adjusted EBITDA rose to $57.5M from $51.2M, a 12% increase year-over-year.

• Cash from operations was $6.9M, down from $41.6M year-over-year, mainly due to higher working capital needs.

• $8.7M was paid in dividends during the quarter.

Outlook and guidance

• Capital expenditures for 2025 are forecasted at $125–135M.

• Management is cautiously optimistic for positive free cash flow and growth in adjusted EBITDA and net income for full-year 2025.

• Full contribution from the Pasadena plant is expected in the second half of 2025, with supply chain savings anticipated.

• Effective tax rate expected at 23–25% for 2025.

• Debt repayments planned at $69M for 2025.